About Echelon Biosciences
Echelon Biosciences is a Healthcare company based in Salt Lake City (United States) founded in 1997, and was acquired by VION Biosciences in August 2024. Reagents and assays for lipid biology research are manufactured. Its website echelon-inc.com draws about 42 thousand monthly visits. Echelon Biosciences offers products and services including Lipids, Bioassays & Kits, Antibodies & Proteins, Peptides, and Biochemical Reagents. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Glycobiology. Its competitors include Avanti Polar Lipids and GlycoT Therapeutics.
Company details
Echelon Biosciences is a biotech company manufacturing reagents and assays with a strong focus on research on lipid biology. The company was formed in 1997 as a spin-off from the Center for Cell Signaling at the University of Utah and changed hands once in 2005 (Aeterna Zentaris) before being acquired by Frontier Scientific Inc. in 2007. The companys focus is on the development of novel assays and reagents for lipid research and drug discovery (with a focus on cancer, liver disease, allergies, Type II diabetes, and anti-infectives). The companys products include chemical reagents (such as phosphoinositide derivatives, inositol phosphates, lipids, isoprenoids, Heme pathway intermediates, and thiol-reactive probes), biological reagents (such as lipid modifying enzymes, kinases and phosphatases, histone modifying enzymes, enzyme inhibitors and substrates, antibodies and antigens, LPA3 selective ligands, lipid coated beads, lipid strips and arrays, lipid coated plates and microarrays, reagents for lipid delivery, cell viability studies, DNARNA purification) and assays (such as kinase assays, phosphatase assays, hydrolase assays, lipid detection assays, biomarker assays, etc). The company also provides protein detection and assay development services to clients.
- Headquarters Salt Lake City, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website echelon-inc.com
- Social LinkedIn
- Acquired by Frontier Chemical (Dec 2007)
- Latest Funding Round$399.29K (USD), Grant
Sep 2024
- InvestorsNIH
& 4 more
- Acquired by
Products & Services of Echelon Biosciences
Echelon Biosciences offers a comprehensive portfolio of products and services, including Lipids, Bioassays & Kits, Antibodies & Proteins, Peptides, and Biochemical Reagents.
Products for lipid research and disease diagnostics
Kits for running samples in assays
Antibodies for protein detection in research
Peptides for scientific synthesis and analysis
Reagents for lipid and cell signaling studies
Funding Insights of Echelon Biosciences
- Total Rounds 22
- Last Round Grant — $399,293
- First Round $200,000
(Nov 2002)
- Investors Count 3
Latest 10 of 22 funding rounds of Echelon Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2024 | $399,293 | Grant | – | – | |
| Jan 2019 | $300,000 | Grant | – | – | |
| Aug 2014 | $224,334 | Grant | – | – | |
| Nov 2011 | $625,241 | Grant | – | – | |
| Sep 2011 | $1.01M | Grant | – | – | |
| Jul 2010 | $248,864 | Grant | – | – | |
| Jun 2010 | $248,864 | Grant | – | – | |
| Jan 2010 | $150,000 | Grant | – | – | |
| Nov 2009 | $150,000 | Grant | – | – | |
| Mar 2009 | $599,834 | Grant | – | – |
5 investors in total: 5 institutional.
Investors in Echelon Biosciences
Echelon Biosciences has secured backing from 5 investors, including institutional investors. Prominent investors backing the company include NIH, HHS and National Science Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
A government-backed foundation providing seed-stage investments to support small businesses. | 1950 | nsf.gov | Arlington, United States | |
Provides end-to-end solutions for drug development, diagnostics, and research manufacturing. | 2023 | vionbiosciences.com | Charlottesville, United States | |
| frontiersci.com |
Investor details for Echelon Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Echelon Biosciences
5 people are tracked at Echelon Biosciences (3 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Bert Israelsen | President | Leadership |
Colin Ferguson | Vice President Of Production | Leadership |
Mark Nelson | VP, Business & Science Development | Leadership |
Kelly Sauder | HR & Accounting Manager | Team |
Cameron Day, Ph.D | Scientist | Team |
Complete people profiles for Echelon Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Echelon Biosciences
5 dated milestones of Echelon Biosciences across 27 years, from founding to its latest funding, stage changes and deals.
- Founded Echelon Biosciences is founded.
- Funding First funding round of $200K.
- Exit Acquired by Frontier Chemical.
- Exit Acquired by VION Biosciences.
- Funding Latest funding round, Grant, of $399K.
Competitors of Echelon Biosciences
Echelon Biosciences has 2 listed competitors in our database. They include Avanti Polar Lipids and GlycoT Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| avantilipids.com | 1969 | Alabaster, United States | 134 | Phospholipids and lipids are manufactured for life science applications. | ||
| glycot.com | 2015 | Ellicott, United States | 5 | Proprietary glycoengineering technologies for therapeutic antibodies are developed. |
Detailed competitors of Echelon Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Echelon Biosciences
The website of Echelon Biosciences (echelon-inc.com) receives about 42.3K visits a month.
- Monthly visits42.3K
▲ 63.1% vs previous month
Websites whose visitors overlap most with Echelon Biosciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
antibody-creativebiolabs.com | antibody-creativebiolabs.com | 100% | #2,485,914 | – | |
gentaur.com | gentaur.com | 96% | #2,063,864 | – | |
| atlasantibodies.com | 96% | 36.6K | #918,880 | View details | |
berryassoc.com | berryassoc.com | 96% | – | ||
acbblocks.com | acbblocks.com | 96% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 31 similar websites and full traffic analytics for Echelon Biosciences
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 31 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Echelon Biosciences (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Echelon Biosciences
Complete news archive for Echelon Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Echelon Biosciences
Echelon Biosciences was founded in 1997 and raised its 1st funding round 5 years after it was founded.
Echelon Biosciences is headquartered in Salt Lake City, United States. It is registered at Salt Lake City, Utah, United States.
Echelon Biosciences is a biotech company manufacturing reagents and assays with a strong focus on research on lipid biology. The company was formed in 1997 as a spin-off from the Center for Cell Signaling at the University of Utah and changed hands once in 2005 (Aeterna Zentaris) before being acquired by Frontier Scientific Inc. in 2007. The companys focus is on the development of novel assays and reagents for lipid research and drug discovery (with a focus on cancer, liver disease, allergies, Type II diabetes, and anti-infectives). The companys products include chemical reagents (such as phosphoinositide derivatives, inositol phosphates, lipids, isoprenoids, Heme pathway intermediates, and thiol-reactive probes), biological reagents (such as lipid modifying enzymes, kinases and phosphatases, histone modifying enzymes, enzyme inhibitors and substrates, antibodies and antigens, LPA3 selective ligands, lipid coated beads, lipid strips and arrays, lipid coated plates and microarrays, reagents for lipid delivery, cell viability studies, DNARNA purification) and assays (such as kinase assays, phosphatase assays, hydrolase assays, lipid detection assays, biomarker assays, etc). The company also provides protein detection and assay development services to clients.
Echelon Biosciences's top competitors include GlycoT Therapeutics and Avanti Polar Lipids.
Echelon Biosciences offers Lipids, Bioassays & Kits, Antibodies & Proteins, Peptides, and Biochemical Reagents.
Echelon Biosciences has 5 investors. Key investors include NIH, HHS, National Science Foundation, VION Biosciences, and Frontier Chemical.
Yes. Echelon Biosciences was acquired by Frontier Chemical in December 2007.